Compare Incyte Corporation (INCY) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Starbucks Corp — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while Starbucks Corp trades at $104.81 (market cap $119.45B). The key difference: Starbucks Corp is far larger — about 5.2× Incyte Corporation's market cap, and Starbucks Corp pays a 2.37% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SBUX | |
|---|---|---|
Market Cap | $23.11B | $119.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $108.37 |
52-Week Low | $67.38 | $78.46 |
Enterprise Value | $19.13B | $142.14B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Starbucks (SBUX) trades at $104.64, down 0.81% on the day, with a bullish technical outlook supported by moving averages. The stock shows mixed earnings performance, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, while revenue growth remains steady. Recent news highlights cost-cutting initiatives, including a $400 million AI-driven software reduction plan, and strong channel development growth of 39% year-over-year in Q2 2026.
The investment outlook is cautiously optimistic, with a consensus price target of $108.86 offering modest upside. Key opportunities include margin expansion from cost efficiencies and dividend growth, but risks involve high valuation multiples, competitive pressures, and inconsistent earnings performance. Analyst sentiment is balanced with 47% buy and hold ratings each.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
